Sugi Predict

Sugi Predict / Compounds / SCHEMBL569991

SCHEMBL569991

SCHEMBL569991

O=C(Nc1nc(C(=O)O)cs1)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.50
▸ KMT2A Q03164 2/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MDM4 O15151 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CASP3 P42574 2/20 0.43
▸ CTSK P43235 1/20 0.43
▸ FABP7 O15540 1/20 0.41
▸ FABP5 Q01469 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2665354 0.85 EPHX2 (0.37) EPHX2KMT2AL3MBTL1NPC1RAB9A
SCHEMBL3586605 0.82 KMT2A (0.50) EPHX2KMT2AMDM4TP53CASP3
SCHEMBL12021343 0.80 CTSK (0.43) EPHX2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL9072517 0.77 EPHX2 (0.48) EPHX2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL3586609 0.76 KMT2A (0.41) EPHX2KMT2AMDM4TP53CASP3
SCHEMBL8366872 0.76 EPHX2 (0.75) EPHX2KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL23164207 0.75 KMT2A (0.48) EPHX2KMT2AMDM4TP53ACHE
SCHEMBL5188515 0.74 EPHX2 (0.53) EPHX2KMT2AMDM4TP53CASP3
SCHEMBL543987 0.74 ALDH1A1 (0.51) EPHX2KMT2ASMN1; SMN2MDM4TP53
SCHEMBL30238049 0.74 KMT2A (0.64) EPHX2KMT2AMDM4TP53CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005805-B2 — — 2018-06-26 — — US disclosed
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY NOVALIX DEUTSCHLAND GMBH (DE) 2017-06-01 — — US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 — — US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 — — US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US disclosed
EP-2601208-B1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2015-02-11 — — EP disclosed
US-8940927-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2015-01-27 — — US disclosed
EP-1383799-A1 PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY TransTech Pharma Inc. (US) 2004-01-28 — — EP disclosed
US-20030225286-A1 Hydantoin-containing glucokinase activators GOODNOW ROBERT ALAN (US) 2003-12-04 — — US disclosed
WO-2003084997-A1 PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY TRANSTECH PHARMA, INC. (US) 2003-10-16 — — WO disclosed
US-20030125315-A1 Probes, systems, and methods for drug discovery TRANSTECH PHARMA, INC. 2003-07-03 — — US disclosed
CN-1427838-A Hydantoin-containing glucokinase activators HOFFMANN LA ROCHE (CH) 2003-07-02 — — CN disclosed
US-6583288-B2 (S,S)-2-((2-(4-(cyclohexyl)methyl-2,5-dioxoimidazolidin-1-yl)-3 -cyclopentylpropanoyl) amino)thiazole-4-carboxylic acid, methyl ester for example; for treatment of diabetes HOFFMAN-LA ROCHE INC. 2003-06-24 — — US disclosed
EP-1280801-A2 HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 — — EP disclosed
US-20010056191-A1 Hydantoin-containing glucokinase activators HOFFMANN-LA ROCHE INC. 2001-12-27 — — US disclosed
WO-2001083478-A2 HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 — — WO disclosed
WO-2001083478-A2 HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005805-B2 — GCKR, GCK, HK1 EPHX2 4456/4885KMT2A 3869/4885L3MBTL1 4159/4885
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 EPHX2 4668/4885KMT2A 3226/4885L3MBTL1 3980/4885
US-20030125315-A1 Probes, systems, and methods for drug discovery ABCG2, EZR, PAICS EPHX2 158/4885KMT2A 4273/4885L3MBTL1 4378/4885
US-20030225286-A1 Hydantoin-containing glucokinase activators GCK, GCKR, HK2 EPHX2 2702/4885KMT2A 2369/4885L3MBTL1 3995/4885
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCGR3B EPHX2 2225/4885KMT2A 2553/4885L3MBTL1 2706/4885
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 EPHX2 4668/4885KMT2A 3226/4885L3MBTL1 3980/4885
US-20010056191-A1 Hydantoin-containing glucokinase activators GCK, GCKR, HK2 EPHX2 2702/4885KMT2A 2369/4885L3MBTL1 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.